Loading...
XNAS
VRDN
Market cap1.37bUSD
Jul 29, Last price  
16.79USD
1D
-2.72%
1Q
23.91%
Jan 2017
235.13%
IPO
98.70%
Name

Viridian Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
4,536.19
EPS
—
Div Yield, %
—
Shrs. gr., 5y
100.62%
Rev. gr., 5y
-41.64%
Revenues
302k
-3.82%
4,406,0424,316,4844,320,0002,538,0003,337,0004,003,0008,386,0004,461,0001,050,0002,963,0001,772,000314,000302,000
Net income
-270m
L+13.55%
-7,211,285-2,159,669-7,890,000-11,328,000-12,674,000-26,512,000-32,703,000-42,420,000-110,984,000-79,416,000-125,444,000-237,734,000-269,949,000
CFO
-232m
L+26.14%
-6,224,802-1,167,793-2,213,000-6,898,000-7,231,000-28,167,000-26,844,000-36,056,000-29,779,000-54,581,000-93,838,000-184,170,000-232,319,000
Earnings
Aug 06, 2025

Profile

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
URL
https://www.viridiantherapeutics.com/
IPO date
Jun 18, 2014
Employees
86
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
302
-3.82%
314
-82.28%
1,772
-40.20%
Cost of revenue
299,337
256,086
136,831
Unusual Expense (Income)
NOPBT
(299,035)
(255,772)
(135,059)
NOPBT Margin
Operating Taxes
(4,430)
Tax Rate
NOPAT
(299,035)
(255,772)
(130,629)
Net income
(269,949)
13.55%
(237,734)
89.51%
(125,444)
57.96%
Dividends
Dividend yield
Proceeds from repurchase of equity
453,660
125,069
292,057
BB yield
-34.86%
-12.83%
-31.16%
Debt
Debt current
513
843
613
Long-term debt
21,095
21,048
5,258
Deferred revenue
284
573
861
Other long-term liabilities
2,024
989
1,172
Net debt
(695,976)
(455,479)
(418,679)
Cash flow
Cash from operating activities
(232,319)
(184,170)
(93,838)
CAPEX
(898)
(797)
Cash from investing activities
(228,651)
(94,252)
(115,126)
Cash from financing activities
457,737
225,670
322,244
FCF
(299,134)
(256,178)
(131,510)
Balance
Cash
717,584
477,370
424,550
Long term investments
Excess cash
717,569
477,354
424,461
Stockholders' equity
(933,869)
(518,514)
(346,003)
Invested Capital
1,628,911
983,146
748,358
ROIC
ROCE
EV
Common stock shares outstanding
67,886
44,755
32,087
Price
19.17
-11.98%
21.78
-25.44%
29.21
47.75%
Market cap
1,301,371
33.50%
974,774
4.00%
937,270
297.77%
EV
666,583
725,811
660,738
EBITDA
(299,035)
(255,250)
(134,804)
EV/EBITDA
Interest
3,046
1,847
486
Interest/NOPBT